KRYS Krystal Biotech, Inc.

315.82USD+0.15%Mkt Cap: 9.36B USDP/E: 42.91

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company c…

Insiders, last 90 daysNet sellers
Institutional holders20 on file

Key Statistics

Company
Market Cap9.36B USD
Enterprise Value8.46B USD
Revenue (TTM)470.02M USD
Gross Profit366.08M USD
Net Income (TTM)204.83M USD
Revenue/Share16.00 USD
Last Price315.82 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees295
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)42.91
P/E (Forward)34.22
PEG—
EV/EBITDA36.92
EV/Revenue17.99
P/S19.91
P/B6.52
EPS (TTM)7.36 USD
EPS (Forward)9.23 USD
52W Range
192.5265% of range382.54
52W High382.54 USD
52W Low192.52 USD
Profitability
Gross Margin94.08%
Oper. Margin48.41%
EBITDA Margin48.73%
Profit Margin52.64%
ROE16.80%
ROA15.36%
ROIC40.21%
ROCE13.10%
Growth
Revenue Growth30.20%
Earnings Growth-22.90%
Cash Flow & Leverage
Operating CF200.87M USD
CapEx (TTM)11.95M USD
FCF Margin47.14%
FCF Yield2.37%
Net Debt-903.26M USD
Net Debt/EBITDA-3.94
Net Debt/FCF-4.08
Balance Sheet
Debt/Equity0.01
Current Ratio7.89
Quick Ratio7.35
Book Value/Sh48.45 USD
Cash/Share30.77 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)388.22 USD
Upside (mean)+22.9%
Target Range284.00 USD – 474.00 USD
284.00+22.9% to mean474.00
# Analysts9
Ownership
Shares Out.29.63M
Float23.66M
Insiders10.64%
Institutions100.91%
Short Interest
Short Ratio11.3d
Short % Float16.81%
Short % Out.10.28%
Shares Short3.04M
Short (prev mo.)3.48M
Technical
SMA 50323.85 (-2.5%)
SMA 200310.06 (+1.9%)
Beta0.65
S&P 52W Chg12.00%
Avg Vol (30d)282.44K
Avg Vol (10d)226.81K
Technical Indicators
RSI (14)51.6
MACD-4.5937
MACD Signal-6.1449
MACD Hist.+1.5512
BB Upper329.21 USD
BB Middle309.69 USD
BB Lower290.17 USD
BB Width12.61%
ATR (14)11.30 USD
Vol Ratio (20d)1.00x

About Krystal Biotech (NASDAQ: KRYS)

›

Krystal Biotech (NASDAQ: KRYS) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 295 employees.

The shares were at 315.82 USD on 19 November 2026, up 57.9% over 52 weeks. Its 52-week range is 192.52 USD to 382.54 USD: the price is 17.4% below the high and 64.0% above the low.

At a market capitalisation of 9.36B USD, it trades at 42.9 times trailing earnings and 34.2 times forward earnings. The median trailing P/E of its 13 largest Biotechnology peers is 33.5, a premium of 28% for KRYS.

Krystal Biotech reports return on equity of 16.8%, an operating margin of 48.4% and revenue up 30.2% year over year.

It holds more cash than debt, a net cash position of 903.26M USD. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 9 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 388.22 USD is 22.9% above the current price. The next earnings report is expected on 16 February 2027.